Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Phio Pharmaceuticals Corp. (RXII)
|
Add to portfolio |
|
|
|
| Price: |
$1.10
| | Metrics |
| OS: |
2.22
|
M
| |
-126
|
% ROE
|
| Market cap: |
$2.44
|
M
| |
|
|
|
Net cash:
|
$11.3
|
M
| |
$5.09
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($12.4)
|
M
| |
|
|
|
EBIT
|
($12.5)
|
M
| |
|
|
| EPS |
($7.29)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 |
| Revenue growth | | | -100.0% | -84.8% | 820.0% | -21.1% | -44.1% | -52.1% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 |
| Gross margin | | | | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Selling, general and administrative | | | | | | | | |
| Research and development | 7.0 | 8.9 | 3.7 | 4.3 | 4.3 | 5.4 | 5.4 | 6.9 |
| General and administrative | 4.5 | 4.6 | 5.1 | 4.7 | 3.2 | 4.0 | 3.6 | 3.3 |
| EBIT | -11.5 | -13.5 | -8.8 | -9.0 | -7.4 | -14.1 | -9.0 | -10.2 |
| EBIT margin | | | | -42795.2% | -5336.2% | -93746.7% | -47447.4% | -30108.8% |
| Pre-tax income | -11.5 | -13.3 | -8.8 | -8.9 | -7.4 | -14.1 | -9.0 | -10.2 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -1.6 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 11.5% | 0.0% | 0.0% |
| Net income | -11.5 | -13.3 | -8.8 | -8.9 | -7.4 | -12.5 | -11.1 | -10.4 |
| Net margin | | | | -42419.0% | -5333.3% | -83013.3% | -58257.9% | -30682.4% |
| |
| Diluted EPS | ($10.10) | ($12.43) | ($1.92) | ($19.33) | ($57.46) | ($5.52) | ($16.41) | ($2.10) |
| Shares outstanding (diluted) | 1.1 | 1.1 | 4.6 | 0.5 | 0.1 | 2.3 | 0.7 | 5.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|